Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

467
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary Volatile Organic Compound Metabolites Are Associated With MASLD/MASH in Humans and Induce Steatosis in Liver Organoids.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System.

Gastro hep advances·2026
Same author

Breath-Based Diagnostics in Liver Diseases: Dynamic Assessment of Hepatic Metabolic Reserve and Liver Fibrosis.

Gastro hep advances·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation.

Med (New York, N.Y.)·2026
Same author

Propelling MASLD trials into the era of non-invasive tests.

The lancet. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Mar 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Laurens A Van Kleef1, Maurice Michel2,3, Naim Alkhouri4

  • 1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Drug Design, Development and Therapy
|March 23, 2026
PubMed
Summary

Resmetirom, a new liver-specific drug, offers hope for metabolic dysfunction associated steatohepatitis (MASH) with fibrosis. It effectively reduces liver fat and improves MASH, marking a significant advancement in treatment.

Keywords:
MASHMASLDfibrosispharmaceutical treatmentresmetirom

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Related Experiment Videos

Last Updated: Mar 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Area of Science:

  • Hepatology
  • Endocrinology
  • Pharmacology

Background:

  • Metabolic dysfunction associated steatotic liver disease (MASLD) affects a third of adults globally, with 10-30% progressing to MASH or fibrosis.
  • Obesity and type 2 diabetes are key risk factors for MASLD progression.

Purpose of the Study:

  • To review the evidence supporting resmetirom's conditional approval for fibrotic MASH.
  • To outline current clinical recommendations and early real-world experiences with resmetirom.
  • To highlight challenges and future directions in managing fibrotic MASH.

Main Methods:

  • Review of clinical trial data and real-world evidence on resmetirom.
  • Analysis of current treatment guidelines and regulatory approvals (FDA, EMA).
  • Discussion of treatment monitoring, patient selection, and combination strategies.

Main Results:

  • Resmetirom is the first therapy approved for MASH with fibrosis, demonstrating MASH resolution and fibrosis improvement.
  • It is a liver-specific thyroid hormone receptor-β agonist that reduces intrahepatic fat.
  • Real-world data show rapid adoption, early improvements in liver stiffness, and frequent use with GLP-1 receptor agonists.

Conclusions:

  • Resmetirom represents a significant therapeutic advance for fibrotic MASH.
  • Optimal positioning within treatment algorithms and combination strategies require further investigation.
  • Long-term impact on liver and cardiometabolic outcomes needs continued monitoring.